Progranulin depletion significantly enhanced cisplatin-dependent cell death as compared to control bladder cancer cells (41), suggesting that progranulin targeting in combination with cisplatin could enhance the therapeutic efficacy of cisplatin-based therapy in invasive bladder tumors. The gene discussed is GRN; the disease is urinary bladder carcinoma.